Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

Purpose

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.

Condition

  • Psoriasis

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Completion of the protocol-required treatment period in an applicable study of BMS-986165 in moderate-to-severe psoriasis - Women must not be pregnant, lactating, or breastfeeding

Exclusion Criteria

  • Any disease or medical condition that the investigator feels that would make the patient unsuitable for this study. - To be eligible for the study, a participant must not have active signs or symptoms of tuberculosis (TB) as judged by the investigator. Other protocol-defined inclusion/exclusion criteria apply

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
BMS-986165
  • Drug: BMS-986165
    Specified dose on specified days
    Other names:
    • Deucravacitinib

More Details

Status
Active, not recruiting
Sponsor
Bristol-Myers Squibb

Study Contact